In short
Gadobenate dimeglumine, also known as MultiHance, is a contrast agent used in magnetic resonance imaging (MRI) to enhance image quality and aid in the diagnosis of various medical conditions. This article examines several clinical trials that have investigated the use of gadobenate dimeglumine in different medical imaging applications, including central nervous system disorders, liver cancer, and cardiovascular diseases.
At a glance
- Primary Uses
- MRI contrast agent for central nervous system, liver, and cardiovascular imaging
- Patient Populations
- Adults and children, including those under 2 years of age
- Dosing
- Varies by study; ranges from 0.05 mmol/kg to 0.15 mmol/kg
- Comparison Studies
- Evaluated against other contrast agents like gadopentetate dimeglumine and gadopiclenol
- Safety Profile
- Generally well-tolerated; specific safety outcomes reported in individual trials
- Imaging Applications
- CNS disorders, liver cancer, coronary artery disease, atrial fibrillation
- Key Outcomes Measured
- Lesion border delineation, internal morphology visualization, contrast enhancement, diagnostic accuracy
- Administration Method
- Intravenous injection, typically as a single bolus
What is Gadobenate Dimeglumine?
Gadobenate dimeglumine, also known by the brand name MultiHance, is a type of contrast agent used in magnetic resonance imaging (MRI) scans. It belongs to a class of drugs called gadolinium-based contrast agents (GBCAs). Contrast agents help enhance the visibility of internal body structures during imaging tests like MRIs.
What is Gadobenate Dimeglumine Used For?
Gadobenate dimeglumine is used to improve the visibility of abnormal structures or lesions in various parts of the body during MRI scans. Some of its main uses include:
- Central nervous system imaging: It helps detect and characterize lesions in the brain and spine.
- Liver imaging: It aids in the detection and characterization of liver lesions, including metastases.
- Cardiovascular imaging: It can be used in MRI scans to assess blood flow and detect heart problems.
- Magnetic resonance angiography (MRA): It enhances the visibility of blood vessels during MRA scans of the carotid, renal, abdominal, and peripheral arteries.
How Does Gadobenate Dimeglumine Work?
Gadobenate dimeglumine contains gadolinium, a rare earth metal. When injected into the bloodstream, it circulates through the body and accumulates in abnormal tissues. The gadolinium alters the magnetic properties of nearby water molecules, which enhances the contrast between normal and abnormal tissues on MRI images. This makes it easier for radiologists to detect and characterize lesions or other abnormalities.
How is Gadobenate Dimeglumine Administered?
Gadobenate dimeglumine is given as an intravenous (IV) injection, usually just before or during an MRI scan. The dose is typically based on your body weight. For most MRI applications, the standard dose is 0.1 mmol/kg (0.2 mL/kg) body weight. However, the exact dose may vary depending on the specific type of scan and the area of the body being examined.
Effectiveness of Gadobenate Dimeglumine
Clinical studies have shown that gadobenate dimeglumine is highly effective in improving the visibility of abnormalities on MRI scans. For example:
- In central nervous system imaging, it has been shown to improve the delineation of lesion borders, visualization of internal lesion structure, and overall lesion contrast enhancement.
- In liver imaging, it has demonstrated effectiveness in detecting and characterizing liver lesions, including in patients with colorectal cancer metastases.
- In cardiovascular imaging, it has been used successfully to assess blood flow and detect coronary artery disease.
Safety and Side Effects
Gadobenate dimeglumine is generally considered safe when used as directed. However, like all medications, it can cause side effects in some people. Common side effects may include:
- Headache
- Nausea
- Dizziness
- Injection site reactions (pain, warmth, or coldness)
Serious allergic reactions are rare but can occur. If you experience symptoms such as difficulty breathing, swelling of the face or throat, or severe dizziness, seek immediate medical attention.
It's important to note that in patients with severely impaired kidney function, gadolinium-based contrast agents have been associated with a rare condition called nephrogenic systemic fibrosis. Your doctor will assess your kidney function before administering gadobenate dimeglumine if you have a history of kidney problems.
Comparison to Other Contrast Agents
Gadobenate dimeglumine has some unique properties compared to other gadolinium-based contrast agents:
- It has a higher relaxivity (a measure of how much it enhances contrast) compared to many other GBCAs, which may allow for better image quality or the use of lower doses.
- It has both extracellular and hepatobiliary properties, meaning it can be used for both general MRI applications and specialized liver imaging.
- Some studies have suggested that it may provide better image quality compared to other GBCAs in certain applications, such as brain tumor imaging.
However, the choice of contrast agent often depends on the specific clinical situation and the preferences of the radiologist or healthcare facility.